NAMS - NASDAQ
NewAmsterdam Pharma Company N.V.
$32.11
+0.75%NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
At a Glance
Live SnapshotNewAmsterdam Pharma Company N.V. Cash Conversion Engine
Cash Flow Quality Analysis
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
NewAmsterdam Pharma Company N.V. Cash Flow Statement
NAMS • NASDAQ
| NewAmsterdam Pharma Company N.V. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
0.0 | -241.6M | -176.9M | -22.6M | -41.8M | -7.1M | |
220K | 113K | 49K | 9K | 5K | 1.2K | |
59.4M | 33.6M | 24.6M | 4.1M | 1.2M | 0.0 | |
-199.5M | 82M | 5.2M | 18.8M | 6.6M | 376.4K | |
(0.0) | (1K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-7.9M | -32.7M | 5.9M | 10.4M | 4.5M | -649.4K | |
-147.8M | -158.6M | -141.2M | 10.7M | -29.5M | -7.3M | |
INVESTING ACTIVITIES | ||||||
-246K | -672K | -24K | -221K | -24K | -16K | |
-296.7M | -62.2M | (0.0) | (0.0) | (0.0) | (0.0) | |
122.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-174.9M | -62.8M | -24K | -221K | -24K | -16K | |
FINANCING ACTIVITIES | ||||||
29.5M | 645.5M | 8.9M | 397M | 84.7M | 0.0 | |
0.0 | 0.0 | 0.0 | 747K | 0.0 | 13.9M | |
0.0 | 14M | 0.0 | -5.8M | 0.0 | 0.0 | |
29.5M | 659.5M | 8.9M | 391.9M | 84.7M | 13.9M | |
CASH FLOW SUMMARY | ||||||
12.8M | -6.8M | 5.1M | 5.2M | -4.7M | 29.5K | |
-280.4M | 431.3M | -127.3M | 407.6M | 50.5M | 6.6M | |
771.7M | 340.5M | 467.7M | 60.1M | 9.6M | 3.1M | |
491.3M | 771.7M | 340.5M | 467.7M | 60.1M | 9.7M | |
-148M | -159.2M | -141.2M | 10.4M | -29.5M | -7.4M |
SEC Filings
NAMS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 24, 2026 | April 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 18, 2026 | February 18, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 18, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 09, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your NAMS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.